These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10426845)

  • 1. A new regimen for heparin use in acute coronary syndromes.
    Hochman JS; Wali AU; Gavrila D; Sim MJ; Malhotra S; Palazzo AM; De La Fuente B
    Am Heart J; 1999 Aug; 138(2 Pt 1):313-8. PubMed ID: 10426845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
    Becker RC; Cannon CP; Tracy RP; Thompson B; Bovill EG; Desvigne-Nickens P; Randall AM; Knatternud G; Braunwald E
    Am Heart J; 1996 Mar; 131(3):421-33. PubMed ID: 8604620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New heparin dosing recommendations for patients with acute coronary syndromes.
    Menon V; Berkowitz SD; Antman EM; Fuchs RM; Hochman JS
    Am J Med; 2001 Jun; 110(8):641-50. PubMed ID: 11382373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb.
    Lee MS; Wali AU; Menon V; Berkowitz SD; Thompson TD; Califf RM; Topol EJ; Granger CB; Hochman JS
    J Thromb Thrombolysis; 2002 Oct; 14(2):91-101. PubMed ID: 12714828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
    Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS
    Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between the aPTT and clinical events in acute coronary syndromes treated with unfractionated heparin.
    Mitrovska S; Jovanova S
    Bratisl Lek Listy; 2006; 107(11-12):422-5. PubMed ID: 17425158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ineffectiveness of a non-weight based heparin regimen in achieving therapeutic activated partial thromboplastin time (aPTT) in acute coronary syndrome.
    Salamonson Y
    Aust Crit Care; 2000 Nov; 13(4):128-33. PubMed ID: 16948203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of a weight-based heparin nomogram for patients with acute coronary syndromes.
    Zimmermann AT; Jeffries WS; McElroy H; Horowitz JD
    Intern Med J; 2003; 33(1-2):18-25. PubMed ID: 12534874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of weight-based versus standard dosing of heparin in patients with unstable angina.
    Folstad J; Caron MF; Nguyen I; White CM
    J Clin Pharm Ther; 2001 Aug; 26(4):283-6. PubMed ID: 11493371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing and testing a system to improve the quality of heparin anticoagulation in patients with acute cardiac syndromes.
    Mungall D; Lord M; Cason S; Treadwell P; Williams D; Tedrick D
    Am J Cardiol; 1998 Sep; 82(5):574-9. PubMed ID: 9732882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.
    Granger CB; Hirsch J; Califf RM; Col J; White HD; Betriu A; Woodlief LH; Lee KL; Bovill EG; Simes RJ; Topol EJ
    Circulation; 1996 Mar; 93(5):870-8. PubMed ID: 8598077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is a standard regime for anticoagulation with heparin in unstable angina adequate?
    Duffy M; Kelly AM; Bau S; Rosengarten P
    Aust N Z J Med; 1997 Dec; 27(6):665-8. PubMed ID: 9483233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Deviation of activated partial thromboplastin time from optimal level after 12 hours of intravenous infusion of unfractionated heparin -- an independent predictor of recurrence and unfavorable 30-day prognosis in patients with myocardial infarction].
    Shalaev SV; Shava VP; Petrik ES; Pushnikova MA; Zhuravleva TD
    Kardiologiia; 2005; 45(10):27-30. PubMed ID: 16234765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome.
    Joncas SX; Poirier P; Ardilouze JL; Carrier N; Fayad T; Farand P
    Obesity (Silver Spring); 2013 Sep; 21(9):1753-8. PubMed ID: 23404940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators.
    Antman EM
    Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S353-60. PubMed ID: 9628449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.
    Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators
    N Engl J Med; 1996 Sep; 335(11):775-82. PubMed ID: 8778585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries.
    Gilchrist IC; Berkowitz SD; Thompson TD; Califf RM; Granger CB
    Am Heart J; 2002 Jul; 144(1):73-80. PubMed ID: 12094191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.